RUNX1 ‐Driven CPXM1 Transcription Promotes Malignant Phenotypes and EMT in Gastric Cancer Cells
Cancer Science · 2026-11 · 117 (11) · 2938-2952
DOI: 10.1111/cas.70475 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, online erschienen am 31.07.2026. Verfasst von Ping Jia und 8 weiteren Autor:innen. Beteiligte Einrichtung: Taizhou Second People's Hospital Affiliated to Yangzhou University, Taizhou, PR China. Hauptthemen laut MEDLINE: Stomach Neoplasms, Core Binding Factor Alpha 2 Subunit, Epithelial-Mesenchymal Transition, Glycoproteins. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Taizhou "Fengcheng Talent Plan" Young Science and Technology Talent Lifting Project, Taizhou Science and Technology Support Program Social Development Project.
Abstract (Originalsprache)
Gastric cancer (GC) remains a leading cause of cancer‐related mortality worldwide, with current treatment strategies largely limited to surgery, chemotherapy, and targeted therapy. Although the glycoprotein CPXM1 has been implicated in tumorigenesis, its functional role and underlying molecular mechanisms in GC remain unclear. In this study, we demonstrated that CPXM1 is significantly upregulated in GC tissues, and that elevated CPXM1 expression is associated with an unfavorable prognosis in GC patients. Both in vitro and in vivo functional assays revealed that CPXM1 significantly promotes GC cell proliferation, invasion, and metastasis. Mechanistically, CPXM1 was found to facilitate epithelial‐mesenchymal transition (EMT), a critical process driving cancer progression. Furthermore, we identified the transcription factor RUNX1 as a direct upstream regulator of CPXM1, which binds to the CPXM1 promoter and transcriptionally activates its expression. Collectively, these findings delineate a previously unrecognized RUNX1/CPXM1/EMT axis that contributes to GC malignant progression, highlighting CPXM1 as a potential diagnostic biomarker and therapeutic target.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Taizhou Second People's Hospital Affiliated to Yangzhou University, Taizhou, PR China.
- Digestive System Department, Taizhou Second People's Hospital Affiliated to Yangzhou University, Jiangsu, PR China.
- Department of General Surgery, the First Medical Center, Chinese PLA General Hospital, Beijing, PR China.
- Department of General Surgery, Taizhou Second People's Hospital Affiliated to Yangzhou University, Taizhou, PR China.
- Department of Clinical Laboratory, Taizhou Second People's Hospital Affiliated to Yangzhou University, Taizhou, PR China.
- Department of Pathology, Taizhou Second People's Hospital Affiliated to Yangzhou University, Taizhou, PR China.
ORCID-Profile: Yu Ouyang
Förderung
- Taizhou "Fengcheng Talent Plan" Young Science and Technology Talent Lifting Project
- Taizhou Science and Technology Support Program Social Development Project
Zitieren
APA
Jia, P., Xu, F., Zhou, T., Wang, P., Chen, H., Zhang, J., Yuan, X., Xu, H., & Ouyang, Y. (2026). RUNX1 ‐Driven CPXM1 Transcription Promotes Malignant Phenotypes and EMT in Gastric Cancer Cells. Cancer Science, 117(11), 2938-2952. https://doi.org/10.1111/cas.70475
Vancouver
Jia P, Xu F, Zhou T, Wang P, Chen H, Zhang J, et al. RUNX1 ‐Driven CPXM1 Transcription Promotes Malignant Phenotypes and EMT in Gastric Cancer Cells. Cancer Science. 2026;117(11):2938-2952. doi:10.1111/cas.70475
BibTeX
@article{Jia2026,
author = {Jia, Ping and Xu, Fengming and Zhou, Tao and Wang, Pingping and Chen, Huiping and Zhang, Jing and Yuan, Xiaochen and Xu, Haoxun and Ouyang, Yu},
title = {RUNX1 ‐Driven CPXM1 Transcription Promotes Malignant Phenotypes and EMT in Gastric Cancer Cells},
journal = {Cancer Science},
year = {2026},
volume = {117},
number = {11},
pages = {2938--2952},
doi = {10.1111/cas.70475}
}
EUVIMED